¼¼°èÀÇ ¿ïÇ÷¼º ½ÉºÎÀü(CHF) Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 89¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, CAGR 13.6%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2034³â¿¡´Â 315¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
Àα¸µ¿ÅÂÀÇ °í·ÉÈ¿Í °íÇ÷¾Ð, ºñ¸¸, ´ç´¢º´ µîÀÇ Áúº´ÀÇ ÀÌȯÀ²ÀÇ »ó½Â¿¡ ÀÇÇØ ½ÉºÎÀüÀÇ ¼¼°èÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ, ½ÃÀåÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. Àα¸ÀÇ °í·ÉÈ ¹× ¸¸¼ºÀûÀÎ °Ç° »óÅÂÀÇ ¸¸¿¬¿¡ µû¶ó ½ÉºÎÀüÀÇ Àå±âÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸´Â °è¼Ó ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ µ¿ÇâÀº ÇコÄɾî ÀÎÇÁ¶ó¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ½ÉÇ÷°ü °Ç°¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í ÀÖ´Â Áö¿ª¿¡¼ ƯÈ÷ µÎµå·¯Áý´Ï´Ù. Áø´Ü ´É·ÂÀÌ Çâ»óµÇ°í ¿¹¹æ ÀÇ·á°¡ Á߽õʿ¡ µû¶ó CHFÀÇ Á¶±â Áø´Ü°ú Ä¡·á°¡ º¸´Ù Çö½ÇÀûÀ¸·Î µÇ°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ ±Þ¼ºÇü°ú ¸¸¼ºÇü ¸ðµÎ¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸°³¹ßÀÌ È°¹ßÇØÁö°í ÀÖ´Â °Íµµ ½ÃÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀÌ ½Å¾à °³¹ß¿¡ ´ëÇÑ ÅõÀÚ¸¦ °ÈÇÏ´Â °¡¿îµ¥ CHF Ä¡·áÀÇ Àü¹ÝÀûÀÎ Àü¸ÁÀº ºü¸£°Ô ÁøÀüµÇ°í ÀÖ½À´Ï´Ù. ´õºÒ¾î ÇコÄɾî Á¤Ã¥, ÀǾàǰ Á¢±Ù¼º °³¼±, Æø³ÐÀº Ä¡·áÁ¦ÀÇ Á¶ÇÕÀÌ ½ÃÀåÀÇ ²ÙÁØÇÑ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶Ç, ½ÃÀå °¢»ç´Â ÆÄÆ®³Ê½ÊÀ̳ª Àü·«Àû Á¦ÈÞ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» Ȱ¿ëÇØ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °ÈÇØ, ¼¼°è Àü°³¸¦ °ÈÇϰí ÀÖ¾î, Àå±âÀûÀÎ ½ÃÀå ¼ºÀåÀ» ÇÑÃþ ´õ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 89¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 315¾ï ´Þ·¯ |
CAGR | 13.6% |
¾à¸®ÇÐÀû Áøº¸´Â CHF Ä¡·á ÇÁ·ÎÅäÄÝÀÇ ÀçÁ¤ÀÇ¿¡ Å« ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¥â Â÷´ÜÁ¦, ACE ¾ïÁ¦Á¦, ÀÌ´¢Á¦ µî ±âÁ¸ÀÇ Ä¡·á°¡ ¿©ÀüÈ÷ CHF Ä¡·áÀÇ ±âº»ÀÎ ¹Ý¸é, »õ·Î¿î ¾àǰ Ŭ·¡½ºº°ÀÌ ÀÓ»óÀû À¯¿ë¼ºÀ¸·Î ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. ¾ÈÁö¿ÀÅٽмö¿ëü-³×ÇÁ¸±¶óÀ̽оïÁ¦Á¦(ARNI)¿Í ³ªÆ®·ý-±Û·çÄÚ¿À½º °ø¼ö¼Ûü-2(SGLT2) ¾ïÁ¦Á¦´Â ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϴµ¥ Å« ÁøÀüÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Å±Ô Ä¡·áÁ¦´Â ±¤¹üÀ§ÇÑ ÀÓ»ó ¿¬±¸¿¡ ÀÇÇØ µÞ¹ÞħµÇ¸ç ÀÔ¿ø·ü°ú »ç¸Á·ü ÀúÇÏ¿¡ À¯¸ÁÇÑ °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç, ÇコÄɾî Á¦°ø¾÷ü¿Í ȯÀÚ ¸ðµÎ¿¡°Ô ¸Å·ÂÀûÀÎ ¼±ÅÃÀÌ µÇ¾ú½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè°ú ±â¼ú Çõ½ÅÀ» ÅëÇØ ÀÌ·¯ÇÑ »õ·Î¿î Ä¡·á¹ýÀº ÇコÄÉ¾î ½Ã½ºÅÛ Àüü¿¡¼ CHF °ü¸® ¹æ¹ýÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù.
¾à¹° µî±Þº°·Î º¼ ¶§ ½ÃÀå¿¡´Â ¥â Â÷´ÜÁ¦, ACE ¾ïÁ¦Á¦, ÀÌ´¢Á¦, ¹Ì³×¶ö ÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü ±æÇ×Á¦(MRA), ¾ÈÁö¿ÀÅٽŠ2 ¼ö¿ëü ±æÇ×Á¦, À̹ٺê¶óÁø, S GLT2 ¾ïÁ¦Á¦, °½ÉÁ¦, ±âŸ µîÀÌ Æ÷ÇԵ˴ϴÙ. 2024³â¿¡´Â ACE ¾ïÁ¦Á¦ ºÎ¹®ÀÌ 24¾ï ´Þ·¯ÀÇ Æò°¡¾×À¸·Î ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù. ±¸Ãâ·üÀÌ ÀúÇÏµÈ ½ÉºÎÀüÀÇ °ü¸®¿¡ ÀÖ¾î¼ ACE ¾ïÁ¦Á¦ÀÇ ¿ªÇÒÀº ¿À·¡ÀüºÎÅÍ È®¸³µÇ¾úÀ¸¸ç, ÀÔ¿øÀ» ÁÙÀÌ°í »ýÁ¸À²À» Çâ»ó½ÃŰ´Â ´É·Âµµ Áõ¸íµÇ¾ú±â ¶§¹®¿¡ ACE ÀúÇØÁ¦ÀÇ °ü·Ã¼ºÀº ³ô½À´Ï´Ù. ÀÌ·¯ÇÑ ¾àÁ¦´Â Àú·ÅÇÑ °¡°Ý, ºê·£µå ¹× Á¦³×¸¯ ÀǾàǰÀ¸·Î¼ÀÇ Æø³ÐÀº ÀÔ¼ö °¡´É¼º, ¼¼°è °¢ÁöÀÇ Ä¡·á °¡À̵å¶óÀο¡ ´ëÇÑ ÀϰüµÈ ½ÂÀÎÀ¸·Î ³Î¸® ó¹æµÇ°í ÀÖ½À´Ï´Ù.
CHF Ä¡·áÁ¦ ½ÃÀåÀº Åõ¿© °æ·Îº°·Î °æ±¸Á¦¿Í ºñ°æ±¸Á¦·Î ±¸ºÐµË´Ï´Ù. °æ±¸Á¦´Â 2024³â¿¡ ½ÃÀåÀÇ 67.2%¸¦ Â÷ÁöÇß½À´Ï´Ù. ±× Æí¸®¼º, »ç¿ë ÆíÀǼº, Àú·ÅÇÑ °¡°Ý ¶§¹®¿¡ CHFÀÇ Àå±â °ü¸®¿¡´Â °æ±¸¾àÀÌ ¹Ù¶÷Á÷ÇÑ ¼±ÅÃÁö°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â CHF Ä¡·áÁ¦ ´ëºÎºÐÀÌ °æ±¸Á¦À̱⠶§¹®¿¡ °í¼Òµæ ±¹°¡¿¡¼³ª Àú¼Òµæ ±¹°¡¿¡¼³ª ȯÀÚÀÇ ¾ÖµåÈ÷¾î·±½º°¡ Çâ»óµÇ°í ºñ¿ë ´ëºñ È¿°ú°¡ ³ôÀº Áúȯ °ü¸®°¡ °¡´ÉÇØÁý´Ï´Ù.
¾à¹° À¯Çüº°·Î, ½ÃÀåÀº ºê·£µå ÀǾàǰ°ú Á¦³×¸¯ ÀǾàǰÀ¸·Î ³ª´µ¾îÁý´Ï´Ù. ºê·£µå ÀǾàǰ ºÎ¹®Àº 2034³â±îÁöÀÇ CAGRÀÌ 13.3%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¼ºÀåÀÇ ¹è°æ¿¡´Â À¯È¿¼º°ú ¾ÈÀü¼ºÀ» ³ôÀÎ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ µµÀÔÀÌ ÀÖ½À´Ï´Ù. ÇコÄɾî Á¦°ø¾÷ü´Â, ±× ±¤¹üÀ§ÇÑ ÀÓ»ó °ËÁõ¿¡ ÀÇÇØ ºê·£µå ¾àÀ» ¼±È£ÇÏ´Â °ÍÀÌ ¸¹°í, ¶Ç ¼¼°è ÀÇ·á ÁöÃâÀÇ Áõ°¡°¡ ½ÅÈï±¹ ½ÃÀå¿¡¼ÀÇ ºê·£µå ¾àÀÇ º¸±ÞÀ» ÁöÁöÇϰí ÀÖ½À´Ï´Ù.
CHF Ä¡·áÁ¦ ½ÃÀåÀÇ À¯Åë ä³Îº°·Î´Â º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹ µîÀÌ ÀÖ½À´Ï´Ù. º´¿ø ¾à±¹Àº 2034³â±îÁö 167¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¼ºÀåÀÇ ¿øµ¿·ÂÀº ÀϹÝÀûÀ¸·Î ¿Ü·¡¿¡¼ ¹ÞÀ» ¼ö ¾ø´Â ¸µ°Å³ª Àü¹®ÀûÀÎ Ä¡·á¸¦ ÇÏ´Â µ¥ º´¿øÀÌ ¼öÇàÇÏ´Â Áß¿äÇÑ ¿ªÇÒÀÔ´Ï´Ù. Ä¡·á Á¢±Ù¹ýÀÌ º¹ÀâÇØÁö¸é¼ º´¿øÀº CHFÀÇ ¼±Áø Ä¡·á¸¦ Á¦°øÇÏ´Â µ¥ Á¡Á¡ ´õ Áß½ÉÀûÀÎ Á¸Àç°¡ µÇ°í ÀÖ½À´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â CHF Ä¡·áÁ¦ ½ÃÀåÀ» 38.5%ÀÇ Á¡À¯À²·Î °ßÀÎÇß½À´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ½ÉºÎÀü Ä¡·á¿¡ ´ëÇÑ ¿Õ¼ºÇÑ ¼ö¿ä¸¦ ¹Ý¿µÇÏ¿© 2024³â 31¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇß½À´Ï´Ù. ÀÌ ³ª¶óÀÇ È®¸³µÈ ÇコÄɾî ÀÎÇÁ¶ó, º¸Çè¿¡ ÀÇÇÑ ÀǾàǰ¿¡ ´ëÇÑ Æø³ÐÀº ¾×¼¼½º, ³ôÀº ÀÎÁöµµ°¡ ½ÃÀåÀ» ¼±µµÇÏ´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå °æÀïÀº ¿©ÀüÈ÷ Ä¡¿Çϸç, AstraZeneca, Novartis, Bayer, Eli Lilly, Boehringer Ingelheim ¹× Merck µî ´ë±â¾÷ÀÌ ¼¼°è ½ÃÀåÀÇ ¾à 45%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº ±â¼ú Çõ½ÅÀ» ÃßÁøÇÏ°í ±ÔÁ¦ »óȲÀÇ ÀÌÁ¤Ç¥¸¦ Ãß±¸Çϸç ÁøÈÇÏ´Â Ä¡·á »óȲ¿¡¼ ¿ìÀ§¸¦ À¯ÁöÇϱâ À§ÇØ Áö¿ªÀû È®´ë¸¦ Áö¼ÓÇϰí ÀÖ½À´Ï´Ù.
The Global Congestive Heart Failure Drugs Market was valued at USD 8.9 billion in 2024 and is estimated to grow at a CAGR of 13.6% to reach USD 31.5 billion by 2034. The increasing global burden of heart failure, driven by aging demographics and the rising incidence of conditions like hypertension, obesity, and diabetes, is significantly contributing to market growth. As the population ages and chronic health conditions become more prevalent, the need for long-term treatment solutions for heart failure continues to grow. This trend is especially prominent in regions with growing access to healthcare infrastructure and increasing awareness of cardiovascular health. Early diagnosis and treatment of CHF are now more feasible thanks to improved diagnostic capabilities and a growing emphasis on preventive care.
The market is also being bolstered by an uptick in research and development activities focused on both acute and chronic forms of the disease. With pharmaceutical companies ramping up investments in new drug development, the overall landscape for CHF treatment is rapidly evolving. Additionally, the combination of supportive healthcare policies, improved drug accessibility, and a wider therapeutic arsenal is reinforcing the market's steady rise. Market players are also leveraging partnerships, strategic alliances, and regulatory approvals to strengthen their product portfolios and enhance global reach, further fueling long-term market growth.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $8.9 Billion |
Forecast Value | $31.5 Billion |
CAGR | 13.6% |
Pharmacological advancements are playing a major role in redefining CHF treatment protocols. While conventional therapies like beta blockers, ACE inhibitors, and diuretics remain fundamental in managing the disease, newer classes of drugs are gaining ground for their clinical benefits. Angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors are making significant strides in improving patient outcomes. These novel therapies are supported by extensive clinical research and have shown promise in reducing hospitalization and mortality rates, making them an attractive option for both healthcare providers and patients. With ongoing clinical trials and innovation, these newer treatments are reshaping how CHF is managed across healthcare systems.
Based on drug class, the market includes beta blockers, ACE inhibitors, diuretics, mineralocorticoid receptor antagonists (MRAs), angiotensin 2 receptor blockers, ivabradine, SGLT2 inhibitors, inotropes, and others. In 2024, the ACE inhibitors segment led the market with a valuation of USD 2.4 billion. Their long-established role in managing heart failure with reduced ejection fraction, combined with their proven ability to reduce hospital admissions and enhance survival, keeps them highly relevant. These drugs are widely prescribed due to their affordability, broad availability in branded and generic formats, and consistent endorsement in treatment guidelines worldwide.
By route of administration, the CHF drugs market is segmented into oral and parenteral formulations. Oral drugs accounted for 67.2% of the market in 2024. Their convenience, ease of use, and affordability make them the preferred option for long-term management of CHF. Most commonly used CHF medications are available in oral formulations, promoting patient adherence and cost-effective disease management across both high- and low-income countries.
In terms of drug type, the market is divided into branded and generic drugs. The branded drugs segment is forecasted to grow at a CAGR of 13.3% through 2034. This growth is attributed to the introduction of innovative therapies that offer enhanced efficacy and safety profiles. Healthcare providers often prefer branded medications due to their extensive clinical validation, while increasing global healthcare spending supports their uptake in developed markets.
The distribution channels in the CHF drugs market include hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are projected to reach USD 16.7 billion by 2034. This growth is driven by the critical role hospitals play in administering intravenous medications and specialized treatments that are typically not available in outpatient settings. As treatment approaches become more complex, hospitals are increasingly central to the delivery of advanced CHF therapies.
Geographically, North America led the CHF drugs market in 2024 with a 38.5% share. The United States, in particular, recorded revenue of USD 3.1 billion in 2024, reflecting strong demand for heart failure treatments. The country's well-established healthcare infrastructure, wide access to medications through insurance, and high awareness levels contribute to its leading market position.
The market remains highly competitive, with major players like AstraZeneca, Novartis, Bayer, Eli Lilly, Boehringer Ingelheim, and Merck collectively holding around 45% of the global market. These companies continue to drive innovation, pursue regulatory milestones, and expand regionally to maintain their edge in the evolving treatment landscape.